Patients receiving enteral nutrition due to difficulty with oral intake or poor nutritional status.
Conditions
Interventions
Base Enteral nutrition formula (1 week ingestion) ->
Base Enteral nutrition formula containing NVIF-02. (4 weeks ingestion)
Sponsors
Mejiro Daini Hospital, Etsudenkai Medical Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hospitalized patients receiving enteral nutrition due to poor oral intake or malnutrition
Exclusion criteria
Exclusion criteria: Patients with complications, e.g., pancreatic fistula (post-pancreaticoduodenectomy) Patients scheduled to receive total parenteral nutrition (TPN) Patients with clinically significant infections Patients with respiratory failure Patients receiving antimicrobial agents Patients with an estimated glomerular filtration rate (eGFR) of stage 4 or lower Patients with severe hepatic dysfunction (e.g., marked jaundice, ascites, or edema) Patients with uncontrolled diabetes mellitus Patients with known allergies to components of the investigational food Patients with a history of hypersensitivity to components of the investigational food Other patients deemed unsuitable by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Defecation frequency Bristol Stool Form Scale Dermal frailty assessment checklist Stratum corneum hydration level Transepidermal water loss | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal gut microbiota composition Fecal short-chain fatty acid (SCFA) concentrations Fecal putrefactive metabolites Fecal pH value | — |
Countries
Japan
Contacts
Public ContactJun Takahashi
Nagase Viita Co., Ltd. Research, Technology and Value Creation Division, Product Value Creation Department
Outcome results
None listed